Loading…
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $308M | $-85M | $-96M | $-58M | -26.1% | 37.2% | - |
| 2024 | $224M | $-82M | $-91M | $-104M | -22.7% | 64.8% | - |
| 2023 | $136M | $-98M | $-106M | $-133M | -37.7% | 81.6% | - |
| 2022 | $75M | $-79M | $-87M | $-83M | -44.2% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 75.01 | 136.19 | 224.50 | 308.05 |
| Cost Of Revenue | 37.93 | 65.14 | 87.40 | 111.83 |
| Gross Profit | 37.09 | 71.05 | 137.10 | 196.23 |
| Operating Expense | 117.81 | 180.22 | 233.71 | 300.08 |
| Operating Income | -80.72 | -109.17 | -96.61 | -103.86 |
| EBITDA | -79.13 | -98.02 | -81.63 | -85.41 |
| EBIT | -81.97 | -101.82 | -86.86 | -91.80 |
| Pretax Income | -87.15 | -105.82 | -91.05 | -95.38 |
| Tax Provision | 0 | 0.08 | 0.37 | 0.19 |
| Net Income | -87.15 | -105.90 | -91.41 | -95.57 |
| Net Income Common Stockholders | -87.15 | -105.90 | -91.41 | -95.57 |
| Total Expenses | 155.74 | 245.36 | 321.11 | 411.91 |
| Interest Expense | 5.18 | 4 | 4.18 | 3.59 |
| Interest Income | 2.50 | 7.55 | 10.89 | 12.22 |
| Research And Development | 28.98 | 48.45 | 62.30 | 71.28 |
| Selling General And Administration | 88.83 | 131.77 | 171.41 | 228.81 |
| Normalized EBITDA | -75.59 | -97.91 | -81.51 | -85.41 |
| Normalized Income | -83.61 | -105.79 | -91.30 | -95.57 |
| Basic EPS | -1.96 | -2.24 | -1.75 | -1.72 |
| Diluted EPS | -1.96 | -2.24 | -1.75 | -1.72 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | -3.54 | -0.11 | -0.11 | 0 |
| Total Unusual Items Excluding Goodwill | -3.54 | -0.11 | -0.11 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -87.15 | -105.90 | -91.41 | -95.57 |
| Reconciled Depreciation | 2.84 | 3.81 | 5.23 | 6.39 |
| Reconciled Cost Of Revenue | 37.93 | 65.14 | 87.40 | 111.83 |
| Net Interest Income | -2.69 | 3.56 | 6.71 | 8.63 |
| Net Income From Continuing And Discontinued Operation | -87.15 | -105.90 | -91.41 | -95.57 |
| Total Operating Income As Reported | -80.72 | -109.17 | -96.61 | -103.86 |
| Diluted Average Shares | 44.40 | 47.26 | 52.12 | 55.54 |
| Basic Average Shares | 44.40 | 47.26 | 52.12 | 55.54 |
| Diluted NI Availto Com Stockholders | -87.15 | -105.90 | -91.41 | -95.57 |
| Net Income Including Noncontrolling Interests | -87.15 | -105.90 | -91.41 | -95.57 |
| Net Income Continuous Operations | -87.15 | -105.90 | -91.41 | -95.57 |
| Other Income Expense | -3.74 | -0.20 | -1.14 | -0.16 |
| Other Non Operating Income Expenses | -0.20 | -0.10 | -1.03 | -0.16 |
| Special Income Charges | -3.26 | 0 | 0 | 0 |
| Other Special Charges | 3.26 | 0 | 0 | 0 |
| Gain On Sale Of Security | -0.28 | -0.11 | -0.11 | 0 |
| Net Non Operating Interest Income Expense | -2.69 | 3.56 | 6.71 | 8.63 |
| Interest Expense Non Operating | 5.18 | 4 | 4.18 | 3.59 |
| Interest Income Non Operating | 2.50 | 7.55 | 10.89 | 12.22 |
| Operating Revenue | 75.01 | 136.19 | 224.50 | 308.05 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| PROCEPT BioRobotics Corporationthis co. | PRCT | $1.2B | - | 3.34 | -26.1% | -10.43 |
| Novavax, Inc. | NVAX | $1.3B | 3.09 | -10.14 | -344.7% | 1.42 |
| Butterfly Network, Inc. | BFLY | $1.3B | - | 6.37 | -39.3% | -20.73 |
| MapLight Therapeutics, Inc. | MPLT | $1.3B | - | 2.91 | -35.2% | -6.14 |
| Olema Pharmaceuticals, Inc. | OLMA |
| $1.2B |
| - |
| 2.40 |
| -33.9% |
| -4.35 |
| Corvus Pharmaceuticals, Inc. | CRVS | $1.2B | - | 17.61 | -25.0% | -26.95 |
| CONMED Corporation | CNMD | $1.2B | 25.12 | 1.14 | 4.6% | 11.20 |
| Kestra Medical Technologies, Ltd. | KMTS | $1.1B | - | 3.95 | -55.4% | -6.60 |
| UroGen Pharma Ltd. | URGN | $1.1B | - | -10.70 | 145.5% | -9.20 |
| Peer Median | - | 14.11 | 2.66 | -34.6% | -6.37 | |